Ukr.Biochem.J. 2016; Volume 88, Issue 6, Nov-Dec, pp. 76-86


The relationship between serum ferritin levels and serum lipids and HDL function with respect to age and gender

Hamit Yasar Ellidag1*, Esin Eren1, Mehmet Akdag2,
Ozlem Giray1, Kemal Kiraz3, Necat Yilmaz1

1Central Laboratories of Antalya Training and Research Hospital,
University of Medical Sciences, Ministry of Health, Antalya, Turkey;
2ENT Clinic of Antalya Ataturk State Hospital, Ministry of Health, Antalya, Turkey;
3Department of Pulmonology, Antalya Ataturk State Hospital,
Ministry of Health, Antalya, Turkey;

Elevated serum ferritin (SFer) levels have been associated with chronic diseases such as coronary heart disease and diabetes mellitus type 2. The aim of this study was to examine the relationship between SFer levels and serum lipid parameters, and how this relation changes in terms of age and gender. Additionally, we investigated a possible relationship between SFer levels and high-density lipoprotein (HDL) function. SFer levels and lipid panel (total cholesterol (TC), triglyceride (TG), low-density lipoprotein-cholesterol (LDL-C) and HDL-C) of 4205 people (3139 women, 1066 men) were examined retrospectively. Study population was classified according to age and gender. Separately, 100 subjects (52 women, 48 men) were randomly recruited to investigate the relation between SFer levels, and HDL dependent paraoxonase-1 (PON1) and arylesterase (ARE) activities. In all age groups, women’s SFer levels were found to be significantly lower and HDL-C levels significantly higher compared to men. In the 50-70 ages range, TC and LDL-C levels of women were found to be significantly higher than those of men (P < 0.01). SFer levels tended to increase with age in women. Correlation analyses revealed a negative correlation between levels of SFer and HDL-C, while positive correlations existed between levels of SFer, and TC, TG and LDL-C. There was no significant correlation between SFer levels and PON1 or ARE activities. The finding that increased SFer levels are accompanied by increased serum TC, TG and LDL-C levels may help us to explain the increased risk of metabolic disorders and cardiovascular disease in postmenopausal women.

Keywords: , , , , ,


  1. Aydin O, Ellidag HY, Eren E, Kurtulus F, Yaman A, Yılmaz N. Ischemia modified albumin is an indicator of oxidative stress in multiple sclerosis. Biochem Med (Zagreb). 2014 Oct 15;24(3):383-9.  PubMed, PubMedCentral, CrossRef
  2. Kell DB. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics. 2009 Jan 8;2:2. PubMed, PubMedCentral, CrossRef
  3. Saito H. Metabolism of iron stores. Nagoya J Med Sci. 2014 Aug;76(3-4):235-254. Review. PubMed, PubMedCentral
  4. Pisano G, Lombardi R, Fracanzani AL. Vascular Damage in Patients with Nonalcoholic Fatty Liver Disease: Possible Role of Iron and Ferritin. Int J Mol Sci. 2016 May 5;17(5). pii: E675. Review. PubMed, PubMedCentral, CrossRef
  5. Fu S, Li F, Zhou J, Liu Z. The Relationship Between Body Iron Status, Iron Intake And Gestational Diabetes: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2016 Jan;95(2):e2383. Review. PubMed, PubMedCentral, CrossRef
  6. Ahluwalia N, Genoux A, Ferrieres J, Perret B, Carayol M, Drouet L, Ruidavets JB. Iron status is associated with carotid atherosclerotic plaques in middle-aged adults. J Nutr. 2010 Apr;140(4):812-6. PubMed, PubMedCentral, CrossRef
  7. Ellidag HY, Kurtulus F, Yaman A, Eren E, Yılmaz N, Aydin O, Bayındır A. Serum iron metabolism markers including hepcidin in multiple sclerosis patients. Neurochem J. 2014;8(3): 226–30. CrossRef
  8. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA. 2004 Feb 11;291(6):711-7.
    PubMed, CrossRef
  9. Sempos CT, Looker AC, Gillum RE, McGee DL, Vuong CV, Johnson CL. Serum ferritin and death from all causes and cardiovascular disease: the NHANES II Mortality Study. National Health and Nutrition Examination Study. Ann Epidemiol. 2000 Oct;10(7):441-8. PubMed, CrossRef
  10. Sempos CT. Do body iron stores increase the risk of developing coronary heart disease? Am J Clin Nutr. 2002 Sep;76(3):501-3. PubMed
  11. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet. 1981 Jun 13;1(8233):1293-4. PubMed, CrossRef
  12. Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992 Sep;86(3):803-11. PubMed, CrossRef
  13. Choi KM, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH. Association among serum ferritin, alanine aminotransferase levels, and metabolic syndrome in Korean postmenopausal women. Metabolism. 2005 Nov;54(11):1510-4. PubMed, CrossRef
  14. Valenti L, Maloberti A, Signorini S, Milano M, Cesana F, Cappellini F, Dongiovanni P, Porzio M, Soriano F, Brambilla M, Cesana G, Brambilla P, Giannattasio C, Fargion S. Iron Stores, Hepcidin, and Aortic Stiffness in Individuals with Hypertension. PLoS One. 2015 Aug 5;10(8):e0134635. PubMed, PubMedCentral, CrossRef
  15. Aronow WS, Ahn C. Three-year follow-up shows no association of serum ferritin levels with incidence of new coronary events in 577 persons aged > or = 62 years. Am J Cardiol. 1996 Sep 15;78(6):678-9. PubMed, CrossRef
  16. Magnusson MK, Sigfusson N, Sigvaldason H, Johannesson GM, Magnusson S, Thorgeirsson G. Low iron-binding capacity as a risk factor for myocardial infarction. Circulation. 1994 Jan;89(1):102-8. PubMed, CrossRef
  17. Mänttäri M, Manninen V, Huttunen JK, Palosuo T, Ehnholm C, Heinonen OP, Frick MH. Serum ferritin and ceruloplasmin as coronary risk factors. Eur Heart J. 1994 Dec;15(12):1599-603. PubMed
  18. Stampfer MJ, Grodstein F, Rosenberg I, Willett WC, Hennekens C. A prospective study of plasma ferritin and risk of myocardial infarction in US physicians [Abstract]. Circulation. 1993;87: 688.
  19. Eren E, Ellidag HY, Aydin O, Yilmaz N. HDL functionality and crystal-based sterile inflammation in atherosclerosis. Clin Chim Acta. 2015 Jan 15;439:18-23.  PubMed, CrossRef
  20. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med. 1979 Jan;90(1):85-91. Review. PubMed, CrossRef
  21. Kamei A, Watanabe Y, Ishijima T, Uehara M, Arai S, Kato H, Nakai Y, Abe K. Dietary iron-deficient anemia induces a variety of metabolic changes and even apoptosis in rat liver: a DNA microarray study. Physiol Genomics. 2010 Jul 7;42(2):149-56.  PubMed, CrossRef
  22. Choi JW, Kim SK, Pai SH. Changes in serum lipid concentrations during iron depletion and after iron supplementation. Ann Clin Lab Sci. 2001 Apr;31(2):151-6.
  23. Ozdemir A, Sevinç C, Selamet U, Türkmen F. The relationship between iron deficiency anemia and lipid metabolism in premenopausal women. Am J Med Sci. 2007 Nov;334(5):331-3. PubMed, CrossRef
  24. Basuli D, Stevens RG, Torti FM, Torti SV. Epidemiological associations between iron and cardiovascular disease and diabetes. Front Pharmacol. 2014 May 20;5:117. Review. PubMed, PubMedCentral, CrossRef
  25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 Jun;18(6):499-502. PubMed
  26. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983 Nov;35(6):1126-38. PubMed, PubMedCentral
  27. Haagen L, Brock A. A new automated method for phenotyping arylesterase (EC based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem. 1992 Jul;30(7):391-5. PubMed, CrossRef
  28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97. PubMed, CrossRef
  29. Tuomainen TP, Punnonen K, Nyyssönen K, Salonen JT. Association between body iron stores and the risk of acute myocardial infarction in men. Circulation. 1998 Apr 21;97(15):1461-6. PubMed, CrossRef
  30. van der A DL, Grobbee DE, Roest M, Marx JJ, Voorbij HA, van der Schouw YT. Serum ferritin is a risk factor for stroke in postmenopausal women. Stroke. 2005 Aug;36(8):1637-41.  PubMed, CrossRef
  31. Wolff B, Völzke H, Lüdemann J, Robinson D, Vogelgesang D, Staudt A, Kessler C, Dahm JB, John U, Felix SB.  Association between high serum ferritin levels and carotid atherosclerosis in the study of health in Pomerania (SHIP). Stroke. 2004 Feb;35(2):453-7. PubMed, CrossRef
  32. Sung KC, Kang SM, Cho EJ, Park JB, Wild SH, Byrne CD. Ferritin is independently associated with the presence of coronary artery calcium in 12,033 men. Arterioscler Thromb Vasc Biol. 2012 Oct;32(10):2525-30. PubMed, CrossRef
  33. Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care. 2004 Oct;27(10):2422-8. PubMed, CrossRef
  34. Li J, Wang R, Luo D, Li S, Xiao C. Association between serum ferritin levels and risk of the metabolic syndrome in Chinese adults: a population study. PLoS One. 2013 Sep 16;8(9):e74168. PubMed, PubMedCentral, CrossRef
  35. Barisani D, Pelucchi S, Mariani R, Galimberti S, Trombini P, Fumagalli D, Meneveri R, Nemeth E, Ganz T, Piperno A. Hepcidin and iron-related gene expression in subjects with Dysmetabolic Hepatic Iron Overload. J Hepatol. 2008 Jul;49(1):123-33. PubMed, CrossRef
  36. Datz C, Felder TK, Niederseer D, Aigner E. Iron homeostasis in the metabolic syndrome. Eur J Clin Invest. 2013 Feb;43(2):215-24. Review. PubMed, CrossRef
  37. Shizukuda Y, Tripodi DJ, Rosing DR. Iron Overload or Oxidative Stress? Insight into a Mechanism of Early Cardiac Manifestations of Asymptomatic Hereditary Hemochromatosis Subjects with C282Y Homozygosity. J Cardiovasc Transl Res. 2016 Aug;9(4):400-1. PubMed, PubMedCentral, CrossRef
  38. Hevi S, Chuck SL. Ferritins can regulate the secretion of apolipoprotein B. J Biol Chem. 2003 Aug 22;278(34):31924-9. PubMed, CrossRef
  39. Cífková R, Krajčoviechová A. Dyslipidemia and cardiovascular disease in women. Curr Cardiol Rep. 2015 Jul;17(7):609. Review. PubMed, CrossRef
  40. Casanova-Esteban P, Guiral N, Andrés E, Gonzalvo C, Mateo-Gallego R, Giraldo P, Paramo JA, Civeira F. Effect of phlebotomy on lipid metabolism in subjects with hereditary hemochromatosis. Metabolism. 2011 Jun;60(6):830-4. PubMed, CrossRef
  41. Houschyar KS, Lüdtke R, Dobos GJ, Kalus U, Broecker-Preuss M, Rampp T, Brinkhaus B, Michalsen A. Effects of phlebotomy-induced reduction of body iron stores on metabolic syndrome: results from a randomized clinical trial. BMC Med. 2012 May 30;10:54. PubMed, PubMedCentral, CrossRef
  42. Ellidag HY, Eren E, Aydin O, Yıldırım M, Sezer C, Yilmaz N. Multiple myeloma: relationship to antioxidant esterases. Med Princ Pract Int J Kuwait Univ Health Sci Cent. 2014;23(1): 18–23. CrossRef
  43. Eren E, Yilmaz N, Aydin O. High Density Lipoprotein and it’s Dysfunction. Open Biochem J. 2012;6:78-93. PubMed, PubMedCentral, CrossRef
  44. Ellidag HY, Aydin O, Eren E, Yilmaz N, Ergin M. Decreased HDL-dependent paraoxonase and arylesterase enzyme activity may indicate a worse prognosis in multiple myeloma. Asian Pac J Cancer Prev. 2014;15(22):9847-51. PubMed, CrossRef
  45. Ellidag HY, Aydin O, Eren E, Yilmaz N, Gencpinar T, Kucukseymen S, Yilmaz A, Ince FDA. Phenotype distribution of the paraoxonase gene in patients with cardiac disease. Arch Med Sci. 2016:1-7.  CrossRef

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.